NCT00152009View on ClinicalTrials.gov

Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

PHASE3CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

January 29, 2003

Primary Completion Date

August 23, 2003

Study Completion Date

August 23, 2003

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

SPD503 (Guanfacine hydrochloride) (2 mg)

DRUG

SPD503 (3 mg)

DRUG

SPD503 (4 mg)

DRUG

Placebo

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY